Personalized Medication Software for BCL-2 Inhibitor in AML Patients Using Machine Learning and Genomics - Trial NCT06295029
Access comprehensive clinical trial information for NCT06295029 through Pure Global AI's free database. This phase not specified trial is sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School and is currently Not yet recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 200 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Timeline & Enrollment
N/A
Mar 01, 2024
Dec 31, 2027
Primary Outcome
Overall survival (OS),Progression-free survival (PFS),Overall adverse event rate,Incidence of grade III and above adverse events
Summary
Severe neutropenia caused by venetoclax,a B-cell lymphoma-2(BCL-2) inhibitor, is the main
 cause of venetoclax tapering, drug discontinuation, and treatment delay. This study combines
 machine learning and genomics, hoping to develop models to predict venetoclax dose in Acute
 myeloid leukemia(AML) patients and compare the efficacy and safety differences of
 model-guided individualized medication regimen with current conventional regimen. According
 to the demographic information, the drug information, the drug concentration of the target
 patients, the laboratory examination, the single nucleotide polymorphism(SNP) information and
 the adverse reactions of the AML patients, and the model was constructed through machine
 learning.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06295029
Non-Device Trial